Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InSilico Medicine Cayman TopCo ( (HK:3696) ) has issued an update.
InSilico Medicine Cayman TopCo has received an additional milestone payment of approximately HKD39 million from Italy-based Menarini Group after the first-in-patient dosing was completed in a Phase I clinical trial for MEN2501, a small molecule inhibitor targeting the kinesin KIF18A motor protein in cancers characterized by chromosome instability. MEN2501, previously known as ISM9682, has been licensed by InSilico to Menarini’s wholly owned subsidiary Stemline Therapeutics under a collaboration with a total potential deal value exceeding USD550 million, underscoring the commercial and strategic significance of the program and reinforcing InSilico’s position as a partner of choice in oncology drug development.
More about InSilico Medicine Cayman TopCo
InSilico Medicine Cayman TopCo is a biotechnology company focused on developing innovative cancer therapies, including small molecule drugs targeting specific cancer-related proteins, and operates through strategic collaborations and licensing agreements with global pharmaceutical partners.
Average Trading Volume: 5,156,516
Current Market Cap: HK$35.96B
Learn more about 3696 stock on TipRanks’ Stock Analysis page.